Johnson & Johnson MedTech Acquires Laminar, Inc. a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million.
Subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia treatment.
Read also – San Francisco-based Every.io Secures $9.5M in Seed Funding
Unlike current commercial catheter-based procedure devices that use plugs to occlude the LAA, Laminar’s novel approach uses rotational motion to eliminate the LAA. Laminar recently received FDA approval for the U.S. pivotal study, which will begin enrollment in early 2024.
LAA closure is an FDA-approved therapy for reducing the risk of thromboembolism in atrial fibrillation patients who are recommended for chronic oral anticoagulation therapy but have an appropriate rationale to seek a non-pharmacologic alternative to chronic oral anticoagulants4.
Randy Lashinski, President & CEO, Laminar said, “For the millions of people living with AFib, stroke risk is a major concern. The team at Laminar is driven by our vision to develop and deliver an innovative solution to help patients live without the fear of stroke, or the need for long-term use of blood thinners, We are looking forward to advancing this vision as part of Johnson & Johnson MedTech.”
Jasmina Brooks, President, Biosense Webster said, “We are excited to welcome Laminar to Johnson & Johnson MedTech, Laminar’s innovative approach will provide Biosense Webster the opportunity to expand our portfolio in this high growth market, complement our electrophysiology and Intracardiac Echo strengths, and deepen our presence with interventional cardiologists and electrophysiologists. Fueled by the global scale and commercial and clinical strength of Biosense Webster, we are excited to explore the possibilities ahead to reach even more patients with critical unmet need.”
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, they unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, they have driven breakthrough scientific innovation to address unmet needs and reimagine health.
Read also- NYC-based Hang Secures $9.2M in Series A Round Funding
